<DOC>
	<DOCNO>NCT00582933</DOCNO>
	<brief_summary>The purpose research study : ( 1 ) determine high dos chemotherapy without total body irradiation allow select stem cell take grow , ( 2 ) determine select stem cell blood marrow take cause complication call graft-versus-host disease ( GvHD ) ( 3 ) evaluate side effect combination chemotherapy drug use transplant . In last 10 year develop chemotherapy combination use T-cell deplete transplant protocol . By use three chemotherapy drug ( IV busulfan , melphalan fludarabine ) , hope good chemotherapy combination kill cancer cell , make graft take , without side effect total body irradiation . The chemotherapy drug test protocol busulfan , melphalan fludarabine , use successfully stem cell transplantation , give together specific regimen . This test study . Our initial trial 1980 's T-cell deplete transplant show less GvHD , overall result transplant well . The reason stem cell take engraft 15 % adult patient . This failure stem cell take leave patient without bone marrow blood cell necessary life . Most stem cell transplant do use bone marrow ( BMA ) obtain donor . However , give medication call G-CSF shot donor , collect peripheral blood stem cell ( PBSC ) use transplant . The advantage approach collect 2-20 time stem cell obtain marrow . It proven large number stem cell graft make difficult patient reject stem cell . Some donor may small provide peripheral blood stem cell may want take G-CSF shot . In case donor marrow collect operating room general anesthesia . Stem cell transplant lead condition know acute graft-versus-host disease GvHD . This disease cause assault certain cell marrow blood ( T-cells ) donor ( graft ) body ( host ) . These T-cells see body foreign attack . The disease cause skin rash , liver disease , diarrhea . Methods develop institution prevent GvHD . These method take T-cells ( responsible GvHD ) marrow blood stem cell transplant . This call `` T-cell depletion '' `` stem cell selection '' . In hospital , use two type method T-cell depletion : one method use peripheral blood stem cell one bone marrow . Both technique successful prevent acute chronic GvHD . You receive T-cell deplete stem cell transplant .</brief_summary>
	<brief_title>Phase II Trial Chemotherapy Alone Regimen IV Busulfan ( Busulfex ) , Melphalan Fludarabine Myeloablative Regimen Followed Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA-Identical , HLA-Non Identical Related Unrelated Donor</brief_title>
	<detailed_description>The trial propose single arm , phase II treatment protocol design examine engraftment , toxicity , graft-versus-host disease ultimate disease-free survival follow transplant derive ( 1 ) HLA-matched sibling related donor , ( 2 ) HLA-compatible unrelated donor ( 3 ) HLA haplo-type mismatch related donor use new chemotherapeutic cytoreductive regimen . Candidates transplant stratify accord donor type . Candidates trial include patient high risk form ALL , AML CML , non-Hodgkin 's lymphoma , myelodysplastic syndrome allogeneic marrow transplant clearly indicate , patient aplastic anemia refractory ATG cyclosporine treatment transfusion dependent . All research participant condition transplantation intravenous busulfan ( busulfex® ) ( 0.8- 1.0 mg/Kg/dose Q6H x 10 dos ) , melphalan ( 70 mg/m2/dose x 2 dos ) fludarabine ( 25mg/m2/day x 5 dos ) . Doses busulfan adjust accord plasma level . All research participant also receive ATG ( Thymoglobulin® ) prior transplant promote engraftment . No drug prophylaxis againstGvHD administer post transplant . All research participant also receive G-CSF post-transplant foster engraftment . The preferred source stem cell peripheral blood stem cell ( PBSC ) induce mobilize treatment donor G-CSF 5-6 day . PBSC obtain 2-3 leukaphereses Isolex® 300i separate CD34+ stem cell column select E-rosette depleted ( E- ) . The CD34 + E peripheral blood progenitor administer research participant complete cytoreduction . If use CD34 + E- PBSC possible , alternative graft consist bone marrow derive stem cell T-cell deplete soybean agglutinin E-rosetting ( SBA-E- ) . Research participant carefully monitor engraftment , chimerism , incidence severity acute chronic GvHD , regimen-related toxicity , characteristic hematopoietic immune reconstitution ultimate survival disease-free survival . This phase II trial design investigate feasibility safety chemotherapy-based cytoreductive regimen plus T-cell deplete peripheral blood stem cell ( PBSC ) bone marrow stem cell transplant ( BMT ) treatment high risk patient advance stage hematologic malignancy . The majority research participant receive graft derive PBSC focus trial . The study population segment three research participant group base type donor use hematopoietic stem cell graft : ( 1 ) HLA-identical sibling relate donor , ( 2 ) HLA-compatible unrelated donor , ( 3 ) HLA-mismatched related donor . A maximum 25 PBSC research participant related group accrue onto study ; maximum 70 PBSC research participant unrelated group accrue . In order reduce patient risk , study design include early termination trial group event excessive graft failure , grade 3-4 acute graft-versus-host disease , early transplant relate mortality accrual period . Excessive failure define differently three donor group . Stopping rule three research participant population utilized . In addition 120 PBSC research participant , anticipate approximately 25 BMT research participant treat across three donor group . These research participant follow conclusion trial descriptive statistic subgroup record .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis : Acute myelogenous leukemia ( AML ) Acute undifferentiated leukemia ( AUL ) ; Acute lymphoblastic leukemia ( ALL ) ; Acute biphenotypic leukemia ( AbiL ) ; Chronic myelogenous leukemia ( CML ) ; Non Hodgkin 's lymphoma ( NHL ) ; Myelodysplastic syndrome ( MDS ) Aplastic anemia ( AA ) Status : CR1 first remission ; CR2 second remission ; CP chronic phase HLAmatched Related donor : Research participant HLAmatched related donor eligible entry protocol . This include healthy related donor genotypically phenotypically match A , B DRB1 locus , test DNA analysis . HLAcompatible Unrelated donor : Research participant relate HLAmatched donor unrelated donor either match A , B DRB1 locus mismatch 1/6 locus ( A , B , DRB1 ) test DNA analysis , eligible entry protocol . HLAmismatched Related donor : Research participant relate unrelated HLAcompatible donor must healthy family member least HLAhaplotype identical recipient . Research participant must healthy HLA compatible relate unrelated donor willing receive GCSF injection undergo apheresis PBSC collection , undergo marrow harvest procedure . Research participants &lt; 55 year . There low age limit . Research participants &gt; 55 year accrue case case basis discussion approval BMT Service . Research participant may either gender ethnic background . Research participant must Karnofsky ( adult ) Lansky ( pediatric ) Performance Status &gt; 70 % Research participant must adequate physical function Active CNS skin leukemic/lymphomatous involvement Female research participant pregnant breastfeed Active viral , bacterial fungal infection Research participant seropositive HIVI/II ; HTLV I/II Research participants undergone prior allogeneic autologous stem cell transplant within previous six month .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Donors</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>Allogeneic marrow transplant</keyword>
	<keyword>Bone marrow transplant</keyword>
</DOC>